Recent research by data‑analytics firm nference reveals a sharp increase in the use of the experimental peptide BPC‑157, commonly marketed alongside TB‑500 as the “Wolverine stack.” The study examined more than 15 million medical records and identified 1,039 patients whose doctors manually noted BPC‑157 use in clinical notes.
Growth in unapproved use
The number of newly documented users rose 33‑fold between 2020 and 2026. Most patients were seeking relief from chronic pain or gastrointestinal symptoms, and the majority obtained the peptide from compounding pharmacies or gray‑market vendors. Male patients grew from 57 % of users in 2020 to 70 % in 2026, while the average age fell from 55 to 49 years. Among the 972 users with recorded race, 96 % were white.
Limited clinical evidence
BPC‑157 has never received FDA approval for any indication. In July, an FDA advisory panel voted to allow pharmacy compounding of the peptide, a move encouraged by U.S. Health Secretary Robert F. Kennedy Jr., despite earlier FDA concerns about safety risks and the lack of human data. The peptide’s absence of a National Drug Code makes tracking its use through electronic health records difficult.
Unclear outcomes
Only about one‑third of the patients had documented treatment responses. Some physician notes described symptom improvement, but the data set lacked standardized measures of efficacy, dosage, route of administration, or treatment duration. When patients stopped BPC‑157, most did so on a doctor’s recommendation; a minority reported adverse effects such as neuropsychiatric, dermatologic, or gastrointestinal symptoms.
Expert commentary
Dr. Flynn McGuire of the University of Utah, who has studied BPC‑157 but was not involved in the analysis, noted that roughly half of the identified patients were also taking other medications—including testosterone, NSAIDs, TB‑500, and corticosteroids—or undergoing physical therapy and surgery. He emphasized that the study lacked a placebo group, standardized indications, and consistent outcome assessments, making it impossible to determine how much improvement could be attributed to BPC‑157 versus other factors.
Market potential
Analysts estimate that, if legitimized, BPC‑157 and related peptides could generate a $2 billion to $3 billion market. However, the current evidence base remains thin, and experts call for randomized controlled trials to establish safety and efficacy before broader adoption.
What patients should know
Patients considering BPC‑157 should discuss the lack of FDA approval and limited safety data with their healthcare providers. Physicians are urged to ask patients directly about any use of unapproved peptides, as many may not disclose such information without prompting.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
